Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06655064 · ClinicalTrials.gov registry record
Registry to Evaluate Long-Term Outcomes in Patients Who Undergo 68-Ga-PSMA-11 PET/CT Imaging Evaluations
A clinical trial, sponsored by Telix Pharmaceuticals (Innovations) Pty Limited.
- Terminated
- Registry status
- 120
- Enrollment target
NCT06655064 is a clinical trial that was terminated before completion, run by Telix Pharmaceuticals (Innovations) Pty Limited. The registered enrollment target is 120 participants.
The verdict
NCT06655064 was terminated before completion, sponsored by Telix Pharmaceuticals (Innovations) Pty Limited.
- TERMINATED
- Registry status
- 120 participants
- Enrollment target
Study Summary
The purpose of this observational research registry is to understand the real-world use of Illuccix PET/CT in prostate cancer, and how results from this testing impact patient's treatment and prostate cancer journey over time. It will follow subjects and the diagnostic testing and therapy they receive for their prostate cancer. Subjects will not be administered any medical diagnostic testing or therapy that they would not have normally undergone outside of participation in the registry.
Interventions
- OTHER None- Observational
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2025-01-30 |
| Est. Completion | 2025-06-17 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06655064
The ClinicalTrials.gov registry entry for NCT06655064 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Telix Pharmaceuticals (Innovations) Pty Limited, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which None- Observational is the first listed.
NCT06655064 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06655064 about?
NCT06655064 is a clinical study titled "Registry to Evaluate Long-Term Outcomes in Patients Who Undergo 68-Ga-PSMA-11 PET/CT Imaging Evaluations". The purpose of this observational research registry is to understand the real-world use of Illuccix PET/CT in prostate cancer, and how results from this testing impact patient's treatment and prostate cancer journey over time. It will follow subjects and the diagnostic testing and therapy they recei...
What is the current status of trial NCT06655064?
This trial is currently terminated. The enrollment target is 120 participants. The study started on 2025-01-30. Estimated completion is 2025-06-17.
What interventions are being tested in trial NCT06655064?
The interventions under investigation include: None- Observational (OTHER).
Who is sponsoring clinical trial NCT06655064?
This trial is sponsored by Telix Pharmaceuticals (Innovations) Pty Limited, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.